Cell Therapy News

Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.

MSC Based Gene Delivery Methods and Strategies Improve the Therapeutic Efficacy of Neurological Diseases

December 8, 2022

[Bioactive Materials] Investigators focus on gene transport technologies for engineering MSCs and the application of strategies for selecting optimal delivery genes.

Postdoc Union Reaches Tentative Agreement with University of California

December 6, 2022

[Science Careers] After weeks of strikes and negotiating involving thousands of early-career researchers across the University of California (UC) system, the union representing UC postdocs and academic researchers announced it has reached a tentative agreement with administrators.

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy

December 5, 2022

[Caribou Biosciences, Inc.] Caribou Biosciences, Inc. announced that the US FDA has granted CB-010 RMAT designation for relapsed or refractory large B cell lymphoma and Fast Track designation for relapsed or refractory B cell non-Hodgkin lymphoma.

FDA Approves First Gene Therapy to Treat Adults with Hemophilia B

December 5, 2022

[FDA] The US FDA approved Hemgenix, an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

Overcoming On-Target, Off-Tumor Toxicity of CAR T Cell Therapy for Solid Tumors

December 5, 2022

[Nature Reviews Clinical Oncology] Scientists summarize current clinical evidence of off-tumor toxicity (OTOT) with CAR T cells in the treatment of solid tumours and discuss the utility of preclinical mouse models in predicting clinical OTOT.

Anti-BCMA/CD19 CAR T Cells With Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy

December 5, 2022

[Blood Cancer Discovery] Researchers conducted a Phase I clinical trial of anti-BCMA CAR T cells with or without anti-CD19 CAR T cells in multiple myeloma patients responding to third- or later- line therapy or high-risk patients responding to first-line therapy, followed by early lenalidomide or pomalidomide maintenance.

The Future of Engineered Immune Cell Therapies

December 5, 2022

[Science] Investigators discuss current progress in treating human disease with immune cell therapeutics, emerging strategies for immune cell engineering, and challenges facing the field, with a particular emphasis on the treatment of cancer.

The Emerging Era of Cell Engineering: Harnessing the Modularity of Cells to Program Complex Biological Function

December 5, 2022

[Science] Scientists discuss the emerging era of biological engineering in which living cells are used as building blocks to address therapeutic challenges.

Activation Priming and Cytokine Polyfunctionality Modulate the Enhanced Functionality of Low-Affinity CD19 CAR T Cells

December 5, 2022

[Blood Advances] Researchers demonstrated that the enhanced functionality of low-affinity CAT CAR T-cells was a consequence of an antigen-dependent priming.

SSTR2 as an Anatomical Imaging Marker and a Safety Switch to Monitor and Manage CAR T Cell Toxicity

December 5, 2022

[Scientific Reports] Using intercellular adhesion molecule 1-specific CAR T cells that secrete interleukin-12 as a model, herein scientists examined the potential of somatostatin receptor 2 (SSTR2) as a safety switch when combined with the SSTR2-specific maytansine-octreotate conjugate PEN-221.

Cord Blood Transplantation for Nonmalignant Disorders: Early Functional Immunity and High Survival

December 5, 2022

[Blood Advances] The authors evaluated the two-year Overall Survival after umbilical cord blood transplantation in patients with non-malignant disorders enrolled on a prospective clinical trial using either 5/6 or 6/6 umbilical cord blood as cell source.

Advantages of the Retroperitoneal Retrocolic Space as the Transplant Site for Encapsulated Xenogeneic Islets

December 5, 2022

[Xenotransplantation] The authors tested a new polymer combination for islet encapsulation and transplantation and explored a new site for xenogeneic islet transplantation in mice.

Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.